Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Jan 07, 2019

SELL
$7.16 - $16.21 $19,045 - $43,118
-2,660 Closed
0 $0
Q3 2018

Oct 12, 2018

BUY
$9.7 - $19.65 $25,801 - $52,268
2,660 New
2,660 $46,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.83B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Dorsey Wright & Associates Portfolio

Follow Dorsey Wright & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Dorsey Wright & Associates with notifications on news.